Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.
Aerosolized delivery of antimicrobial agents is an attractive option for management of pulmonary infections, as this is an ideal method of providing high local drug concentrations while minimizing systemic exposure. With the paucity of consensus regarding the safety, efficacy, and means with which to use aerosolized antimicrobials, a task force was created by the Society of Infectious Diseases Pharmacists to critically review and evaluate the literature on the use of aerosolized antiinfective agents. This article summarizes key findings and statements for preventing or treating a variety of infectious diseases, including cystic fibrosis, bronchiecstasis, hospital-acquired pneumonia, fungal infections, nontuberculosis mycobacterial infection, and Pneumocystis jiroveci pneumonia. Our intention was to provide guidance for clinicians on the use of aerosolized antibiotics through evidence-based pharmacotherapy. Further research with well-designed clinical trials is necessary to elucidate the optimal dosage and duration of therapy and, of equal importance, to appreciate the true risks associated with the use of aerosolized delivery systems.
Le
Jennifer
J
University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California 92093-0714, USA. jenle@ucsd.edu
Ashley
Elizabeth Dodds
ED
Neuhauser
Melinda M
MM
Brown
Jack
J
Gentry
Chris
C
Klepser
Michael E
ME
Marr
Ann Marie
AM
Schiller
Daryl
D
Schwiesow
Joshua N
JN
Tice
Sally
S
VandenBussche
Heather L
HL
Wood
G Christopher
GC
D000280:Administration, Inhalation; D000336:Aerosols / Q000008:administration & dosage*; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D032921:Consensus; D015507:Drugs, Investigational / Q000008:administration & dosage; D006801:Humans; D009330:Nebulizers and Vaporizers; D010353:Patient Education as Topic; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000517:prevention & control*
D000336:Aerosols; D000890:Anti-Infective Agents; D015507:Drugs, Investigational